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Benefit of chemotherapy as part of treatment for HPV
DNA-positive but p16-negative squamous cell carcinoma
of the oropharynx
E Junor*,1, G Kerr1, A Oniscu2, S Campbell1, I Kouzeli3, C Gourley4 and K Cuschieri3
1Edinburgh Cancer Centre, Western General Hospital, Crewe Road South, Edinburgh EH4 2XU, UK; 2Department of Pathology, Royal Inf irmary of
Edinburgh, Edinburgh EH16 4SA, UK; 3Scottish HPV Reference Laboratory, Royal Inf irmary of Edinburgh, Edinburgh EH16 4SA, UK; 4University of
Edinburgh Cancer Research UK Centre, Institute of Genetics and Molecular Medicine, Crewe Road South, Edinburgh EH4 2XR, UK
BACKGROUND: To determine (a) the cause of an improvement in survival from oropharyngeal squamous cell carcinoma (OSCC) in
South East Scotland and (b) whether this improvement was human papillomavirus (HPV) and p16 subtype-dependent.
METHODS: Clinicopathological characteristics and outcome data for patients referred with OSCC from 1999 to 2001 (Cohort-1) and
2003 to 2005 (Cohort-2) were obtained. Molecular HPV detection and immunohistochemistry for p16 were performed from
paraffin blocks.
RESULTS: Cohort-1 and Cohort-2 contained 118 and 136 patients, respectively. Kaplan–Meier analysis revealed significantly improved
survival in Cohort-2 (Po0.0001). Sub-classification according to HPV and p16 status revealed no improvement in survival in Class-I
(HPVve/p16ve; 47 patients) or Class-III (HPVþ ve/p16þ ve; 77 patients). However in Class-II (HPVþ ve/p16ve; 56 patients)
an increase in 5-year cause-specific survival from 36% in Cohort-1 to 73% in Cohort-2 was detected (P¼ 0.0001).
Proportional hazards analysis of 217 patients treated radically demonstrated that significant variables were p16 (Po0.0001), N stage
(P¼ 0.0006) and cohort (P¼ 0.0024). Removing cohort from the variables offered to the model showed that, whereas
p16 (Po0.0001) and N stage (P¼ 0.0016) remain significant, chemotherapy (P¼ 0.0163) and T stage (P¼ 0.0139) are now
significant. This suggests that much of the cohort effect is due to the higher use of chemotherapy in the second cohort.
CONCLUSION: These data suggest that HPVþ ve/p16ve patients constitute a separate subclass of OSCC who may particularly
benefit from chemotherapy. They imply that p16 status cannot be considered a surrogate for HPV status, and those trials to
de-escalate treatment in HPVþ ve OSCC should take p16 status into account.
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It is now well established that the incidence of oropharyngeal
squamous cell carcinoma (OSCC) has increased over the past
20 years in the United States of America, Europe and Australia
(Frisch et al, 2000; Nasman et al, 2009; Hong et al, 2010).
This demographic change has been linked to an increase
in human papillomavirus (HPV)-associated tumours, particularly
in younger, White, non-smoking males (Gillison et al, 2008). For
example, in Stockholm the percentage of HPV-related squamous cell
cancers of the tonsil has increased over the past two decades such
that for the period 2006–2007, 93% were HPVþ ve. Population-
based data from Scotland have shown that the rate of OSCC
increased more than any other cancer, with a 2.9-fold increase in
men (European Age-Standardised Rate per 100 000 at risk, EASR,
1.96–5.95) and a 2.4-fold increase in women (EASR 0.68–1.54) in the
period between 1987 and 2006 (Junor et al, 2010). The prevalence/
association of HPV in this group has yet to be quantified.
There is a growing evidence base to suggest that HPVþ ve OSCC
have a better prognosis than HPVve tumours, suggesting a
clinical utility for HPV testing (Lindel et al, 2001; Fakhry et al,
2008). Retrospective analysis of HPV status in large randomised
clinical trials has shown that the survival of HPVþ ve non-
smokers was significantly better than HPVþ ve smokers and
HPVve non-smokers, with the HPVve smokers having the
worst survival (Gillison et al, 2009; Ang et al, 2010).
Other studies have looked at HPV status, and its association
with p16 gene expression and survival (with p16 acting as a
surrogate of deregulated early viral gene expression). A consensus
has emerged indicating that the best survival is associated with
HPVþ ve/p16þ ve status and worst survival with HPVve/
p16ve status (Weinberger et al, 2006; Smith et al, 2008). However
prognosis of the discordant groups (HPVve/p16þ ve and
HPVþ ve/p16ve) is more controversial. p16 has been suggested
as a surrogate for HPV positivity (Klaes et al, 2002).
In 2002 there was a change in treatment policy for oropharyn-
geal cancer in the South East Scotland Cancer Research Network.
As such survival analysis was performed comparing all patients
treated between 1 January 1999 and 31 December 2001 with those
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treated between 1 January 2003 and 31 December 2005. This
revealed a greater than anticipated improvement in survival for the
latter cohort. We sought to determine whether the
change in survival was driven by the increased prevalence of
HPV-associated tumours or the change in treatment.
PATIENTS AND METHODS
Patients
The Edinburgh Cancer Centre is the regional referral centre for all
patients with head and neck cancer for a population of 1.4 million.
2002 was a year of transition, with a change in patient management
policy for patients with squamous cell cancer of the oropharynx
treated at the Edinburgh Cancer Centre. A comprehensive database
had been collected for all patients diagnosed between 1999 and
2001 as part of a national audit, and a comparative population-
based cohort of all patients in South East Scotland diagnosed
between 2003 and 2005 was used to determine whether the change
in treatment had resulted in any change in survival. Checking
against the Scottish Cancer Registry confirms that this study is
truly population-based.
Treatment of OSCC prior to 2002 had been preferentially
surgery±postoperative radiation or radiation alone. Neck
dissection was performed for N2/N3 disease pre-radiotherapy in
Cohort-1. Concurrent chemotherapy with radiation became
the treatment of choice after 2002. During the period of the
later cohort, policy changed to performing a neck dissection after
concurrent chemo-irradiation if a complete response had been
achieved at the primary site.
Histological diagnosis of SCC of the oropharynx was confirmed
by pathology review. Patients who presented with metastatic neck
nodes and were only later found to have an oropharyngeal
carcinoma were excluded. Patients without paraffin blocks were
excluded from the subgroup analysis according to HPV/p16 status
but were included in overall survival analysis.
Clinicopathological characteristics and outcome data for all
patients were obtained from the electronic database and case
notes. Radiotherapy was administered with curative intent over a
4-week schedule in the first cohort and a 6.5-week schedule in the
second cohort. A radiobiological correction was made to convert
both schedules into 2 Gray Equivalent Dose (EQD) using an a/b
ratio of 10. Intensity-Modulated Radiation Therapy was not used.
The chemotherapy regimens used were cisplatin or carbo-
platin±5-fluorouracil. Methotrexate was used in a small number
of patients in the first cohort as part of the UKHAN trial. Patients
were followed up by the specialist team.
Ethical approval for this study was obtained from Lothian
Research Ethics Committee 2.
Methods
One representative paraffin block was selected for each case. One
10-mm paraffin section was used for HPV analysis and one 3-mm
section was used for p16 immunohistochemical analysis. For
molecular HPV detection, nucleic acid extraction was performed
by digesting the section for 15 h in proteinase-K (Gilbert et al,
2007). The crude lysate was purified using the Qiagen DNA mini
kit (Qiagen Ltd, Crawley, UK) according to the manufacturer’s
instructions. Human papillomavirus amplification and genotyping
of extract was performed using the INNO-LiPA HPV Genotyping
Extra assay (INNOGENETICS N.V, Gent, Belgium). This is a
commercial assay, which involves hybridisation of a short HPV
amplicon (generated using SPF10 primers) to a probe array for
detection of HPV types, 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 43, 44,
45, 51, 52, 53, 54, 56, 58, 59, 66, 68, 69/71, 70, 73, 74 and 82.
The assay also incorporates detection of the human HLA-DPB1 to
check for specimen integrity/eligibility for molecular processing. If
a sample tested negative for both the human gene and for the HPV
types being tested then it was considered ‘invalid’ for HPV testing
(owing to lack of amplifiable human DNA sequence).
Immunohistochemical staining for p16 was performed using the
automated Vision BioSystems BOND-maX IHC staining instru-
ments. p16 was detected using the CINtec Histology kit (clone
E6H4 provided ready to use without dilution from MTM
Laboratories, Heidelberg, Germany) according to the manufac-
turer’s protocol. (Appendix Protocol A2) Negative controls
(normal cervix) and positive controls (cervical high-grade
intraepithelial neoplasia) were included with each series. Staining
was then scored as negative, focal positive and positive on the basis
of both nuclear and cytoplasmic staining within the tumour
component. Diffuse and continuous cytoplasmic and nuclear
staining throughout the tumour cells was considered a positive
reaction. A negative reaction was considered in cases where
tumour cells were completely negative or staining was identified
within the non-dysplastic surface squamous epithelium; benign
sub-epithelial sero-mucinous glands; or the cytoplasm of scattered
histiocytes, peri-tumoural fibroblasts or follicular dendritic cells
within the mucosal associated lymphoid tissue.
Statistical considerations
The Kaplan–Meier method was used to calculate the actuarial
cause-specific survival rates and relapse rates (Kaplan and Meier,
1958). The Mantel–Cox test was used for statistical comparison
between curves. Exploratory univariate analysis of survival looked
at cohort, age, sex, deprivation category, smoking, drinking,
sub-site, grade, stage, T stage, N stage, radical surgery, radical
radiotherapy, radiation dose (EQD), radical chemotherapy,
p16 and HPV status for radically treated patients. A Cox
proportional hazards regression model (PH) was used to assess
the independent prognostic significance of these variables. Not all
radically treated patients could be included in the proportional
hazards analyses owing to incomplete data for some variables.
Smoking, drinking, grade and HPV status were removed from
consideration as they were the variables with the most incomplete
data and were not significant in the preliminary PH analysis. The
P-value for exclusion of a variable was set at the arbitrary level of
0.2. A significance level of 0.05 was used for the exploratory
analysis and 0.01 for any quoted results, unless otherwise specified.
Confidence intervals (CIs) are quoted at the 95% level.
RESULTS
Patient characteristics
There were 118 patients in Cohort-1 (1999–2001) and 136 in
Cohort-2 (2003–2005). Minimum follow-up was 83 and 48 months,
respectively. Table 1 summarises the pre-treatment patient/disease
characteristics and the treatments administered.
The two cohorts were similar apart from the following: p16
(P¼ 0.0243) and HPV (P¼ 0.0018) were more often positive in
Cohort-2. Surgery was more often the treatment of choice in
Cohort-1 (P¼ 0.0017), but radiation (P¼ 0.0292) and chemother-
apy (Po0.0001) were more frequently used in Cohort-2 (Table 2).
Survival
The 2-year cause-specific survival was 59.3% (CI 50.3–68.3%) in
Cohort-1 and 78.2% (CI 71.1–85.2%) in Cohort-2. The actuarial
estimate was 44.9% (CI 35.4–54.4%) at 5 years in Cohort-1
compared with 72.0% (CI 64.2–79.8%) in Cohort-2. Kaplan–Meier
analysis revealed a significant difference in survival between the
two cohorts (Figure 1, Po0.0001).
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Univariate survival analysis revealed p16, HPV, cohort, alcohol
and smoking as having a significant effect on cause-specific
survival (Table 2). Twenty-five patients received no treatment and
eight received only palliative treatment. These 33 patients were
excluded from the proportional hazards analysis. The variables
age, sex, socio-economic deprivation category (DepCat), cohort, T,
N, p16, surgery or not, XRT or not, EQD, and chemotherapy or not
were considered, allowing 217 patients (64 events) to be included
(Table 3).
Significant variables in order were p16 (HR 0.2 (95% CI 0.107–
0.384) Po0.0001), nodal status (HR 1.585 (1.218–2.063)
P¼ 0.0006) and cohort (HR 0.454 (0.273–0.0757) P¼ 0.0024).
Removing cohort from the variables offered to the model shows
that p16 (Po0.0001) and nodal status (P¼ 0.0016) are still
significant. Relaxing the significance level to 0.05% would allow
T stage and chemotherapy into the model.
Similarly, offering HPV as a possible prognostic factor with a
0.05% significance would also indicate that it might be of
prognostic significance, although in this case only 163 patients
(64% of the group under study) are included in the analysis. In the
92 p16þ ve patients there were 13 events and no significant
prognostic variables. However, if HPV is included (only 80
patients, 12 events) then HPV is significant (Po0.0001).
In the 125 p16ve patients there were 51 events. Significant
variables were N stage (P¼ 0.0017), chemotherapy (P¼ 0.0099)
and T stage (P¼ 0.0280).
In the HPVþ ve patients, only p16 was significant, whereas in
the HPVve patients, there were no significant variables.
If prognostic group (according to the combination of HPV
and p16) is included as a possible prognostic variable instead of
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Figure 1 Kaplan–Meier plots illustrating the overall survival of patients in
Cohort-1 (1999–2001) and Cohort-2 (2003–2005).
Table 1 Patient demographics and clinical characteristics
Total 1999–2001 2003–2005
Characteristic No. % No. % No. %
No. of cases 254 100 118 46 136 54
Sex
Male 182 72 85 72 97 71
Female 72 28 33 28 39 29
Age (years)
Mean 60 60 60
Disease site
Tonsil 119 47 63 53 56 41
Soft palate 31 12 10 8 21 15
Base of tongue 73 29 34 29 39 29
Oropharynx, NOS 31 12 11 9 20 15
Staging
T1–2 124 49 63 53 61 45
T3–4 130 51 55 47 75 55
N0 77 30 37 31 40 29
N1–3 176 69 81 69 95 70
Nx 1 0 0 0 1 1
Stage I – II 49 19 27 23 22 16
Stage III – IV 205 81 91 77 114 84
P16
Positive 94 37 35 30 59 43
Negative 153 60 79 67 74 54
NK 7 3 4 3 3 2
HPV
Positive 133 52 48 41 85 63
Negative 51 20 32 27 19 14
Invalid 63 25 34 29 29 21
NK 7 3 4 3 3 2
Treatment
None 25 10 16 14 9 7
Palliative chemo 6 2 4 3 2 1
Surgery alonea 12 5 6 5 6 4
Surgery+PORT 22 9 19 16 3 2
Surg, POCRT 3 1 1 1 2 1
XRT alone 64 25 43 36 21 15
Chemo and XRT 19 7 1 1 18 13
Concom chemo/XRT 103 41 28 24 75 56
Smoking
Never 35 14 11 9 24 18
Ex 44 17 16 14 28 21
Current 158 62 78 66 80 59
NK 17 7 13 11 4 3
Drinking
Never 13 5 5 4 8 6
Previous 20 8 6 5 14 10
Social 102 40 47 40 55 40
Excess 99 39 45 38 54 40
NK 20 8 15 13 5 4
Abbreviations: Chemo and XRT¼ neoadjuvant chemotherapy followed by radiation
alone; Concom¼ concomitant chemotherapy and radiation; POCRT¼ postopera-
tive chemoradiation; PORT¼ postoperative radiation; Surg, XRT+chemo¼ surgery,
postoperative concomitant chemotherapy and radiation. aPatients counted as having
surgery alone are those treated with radical surgery for the primary tumour, not
those solely undergoing neck dissection.
Table 2 P-values for associations between variables and univariate
survival analysis
Associations (significant P from v2-test)
P
Cohort HPV p16
Univariate
CSSR
Cohort 0.0018 0.0243 0.0006
Sex 0.0314 0.1781
Age 0.0048 0.0646
Smoking 0.0774 0.0018 o0.0001 0.045
Drinking 0.0783 o0.0001 0.0127
DepCat 0.2430
T 0.2057
N 0.0016 0.5815
Stage 0.0054 0.3303
Grade 0.0176 o0.0001 0.1873
p16 0.0243 o0.0001 o0.0001 (1)
HPV 0.0018 o0.0001 o0.0001 (2)
Surgery 0.0017 0.9507
XRT 0.0292 0.0113 0.0002 0.3538
Chemo o0.0001 0.0181 o0.0001 0.1954
Abbreviations: CSSR¼ cause-specific survival rate; DepCat¼ socioeconomic
deprivation category. (1) test statistic 35.0; (2) test statistic 24.0.
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HPV and p16 separately, then it is the only significant variable
(Po0.0001, HR 1.642, CI 1.304–2.067), but only 159 patients and
42 events are analysed.
Effect of smoking
Cause-specific survival for 1, 2 and 5 years for never smokers was
91.3%, 91.3%, 82.0%; for past smokers 90.7%, 83.5%, 67.2%; and
for current smokers 67.3%, 62.5% and 55.8%.
Smoking was significant in the univariate analysis (Po0.0045).
Of the 89 p16þ patients for whom smoking status was recorded,
41.6% smoked, 27% were past smokers and 31% were never
smokers. In the p16 group 82% were current smokers, 14% past
smokers and only 4% were never smokers. Looked at another way
25% of current smokers were p16þ , 54% of past smokers were
p16þ and 82% of never smokers were p16þ .
In the proportional hazard model smoking did not reach
statistical significance, but this may have been because p16 was the
most significant variable and was strongly associated with
smoking.
Effect of HPV and p16 status on overall survival
A total of 184 patients had valid results on HPV testing, 133 of
whom were positive (Figure 2). One hundred and twenty-two were
HPV type-16-positive, of whom seven were also positive for
another high-risk HPV type. Other subtypes detected without the
presence of HPV-16 were HPV-6, 18, 33, 35, 51, 52 and 66. Of these
184 HPVþ ve patients, 77 tested positive for p16. Where HPV and
p16 were both available, groups were allocated as HPVþ ve/
p16þ ve (77), HPVþ ve/p16ve (56) and HPVve/p16ve (47).
There were only four patients who were HPVve/p16þ ve.
Appendix Table A1 shows the sex, age, stage, anatomical sub-
site, grade, smoking, drinking, socio-economic deprivation cate-
gory and treatment for each class by cohort. The second cohort
contained more patients who had never smoked, and more
patients who were HPVþ ve or p16þ ve (P¼ 0.002 and
P¼ 0.024, respectively). Treatment in the second cohort was more
likely to involve radical radiotherapy (Table 2, P¼ 0.03) or
chemotherapy (Po0.0001), and less likely to have included radical
surgery to the primary site. Human papillomavirus (HPV)þ ve
patients include fewer smokers (P¼ 0.004) and are more likely to
have had grade-3 tumours (P¼ 0.02). p16þ ve patients are
younger (mean age 56.1 years compared with 62.3 years for
p16-negative patients; Po0.0001, t-test). They are more likely to be
male (P¼ 0.03), less likely to be smokers (Po0.0001) or heavy
drinkers (Po0.001), more likely to have grade-3 tumours
(Po0.0001) and to have nodal involvement (P¼ 0.002).
p16 and HPV are associated (Po0.0001) with 95% of p16þ ve
patients being HPVþ ve, although only 58% of HPVþ ve patients
were p16þ ve.
Figure 3A shows the survival curves for each of the classes,
Class-III (HPVþ ve/p16þ ve), Class-II (HPVþ ve/p16ve) and
Class-I (HPVve/p16ve), by cohort. Survival for classes I and III
varies little between the two cohorts. However in Class-II
(HPVþ ve/p16ve) 5-year survival rises from 36% in Cohort-1
to 73% in Cohort-2 (P¼ 0.0001). When the prognostic features of
the HPVþ ve/p16ve groups from cohorts 1 and 2 were
compared, the only factor significantly associated with survival
was chemotherapy use (P¼ 0.0143). All other demographic and
treatment differences were not significantly associated with
survival (Appendix Table A2).
Relapse
The 33 patients who were not treated or who received only
palliative treatment have been excluded from this analysis. A total
of 25 patients (13.1%) failed to achieve a complete response in
both primary and nodes (5 were N0) and have been counted as
relapsed at time 0. The overall relapse rate was 29.2% (CI 23.1–
35.3%) at 2 years and 35.3% (CI 28.7–41.8%) at 5 years. The loco-
regional relapse rate was 27.5% (CI 21.5–33.5%) at 2 years and
31.5% (CI 25.2–37.9%) at 5 years. There have been no loco-
regional relapses after 4 years.
No complete response was achieved by 6.6% of the 76 HPVþ
ve/p16þ ve patients; 14.9% of the 47 HPVþ ve/p16ve patients;
Table 3 Results of PH analysis
Variable P Hazards ratio CI for hazards ratio
p16 o0.0001 0.211 0.111–0.398
N stage 0.0011 1.551 1.192–2.017
Cohort 0.0037 0.471 0.283–0.0783
Excluding cohort
p16 o0.0001 0.20 0.106–0.377
N stage 0.0034 1.471 1.136–1.903
T stage 0.0139 1.366 1.065–1.752
Chemotherapy 0.0163 0.464 0.248–0.868
Case identification
Patients for survival analysis
Block availability
HPV test validity
Cohort 1: 1999–2001 Cohort 1: 2003–2005
Excluded;
metastatic neck
nodes with no
primary (n =2)
118 Patients 136 Patients
No FFPE
block available
(n =3)
FFPE block
available
(n =133)
FFPE block
available
(n =114)
No FFPE 
block available
(n =4)
Invalid (n =34) Valid (n =80) Invalid (n =29) Valid (n =104)
Excluded;
metastatic neck
nodes with no
primary (n =2)
Patients presenting
with OSCC (n =120)
Patients presenting
with OSCC (n =138)
Figure 2 Illustration of case identification and disposition.
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and 22.2% of the 36 HPVve/p16ve patients. Corresponding
2-year loco-regional relapse rates were 13.5%, 28.2% and 43.8%,
and 5-year relapse rates 13.5%, 36.2% and 51.8%, respectively.
The rate of loco-regional and metastatic relapse between the
cohorts according to HPV and p16 status is shown in Figure 3B
and C. Although metastatic relapse is fairly rare, the only significant
differences between the cohorts are that both loco-regional
(P¼ 0.001) and metastatic relapse (P¼ 0.023) are more frequent in
the earlier cohort in the HPVþ ve/p16ve patients. Combined with
the earlier findings this suggests that chemotherapy may have a role
in preventing loco-regional and distant relapse, most specifically in
the HPVþ ve/p16ve subgroup of patients.
DISCUSSION
This study was the result of an observation that the disease-specific
survival for patients with oropharyngeal squamous cell cancer
treated between 2003 and 2005 was significantly better than a
similar population treated between 1999 and 2001. The data truly
reflect a geographical population but do suffer from all the known
problems of retrospective studies. The prevalence of HPVþ ve
tumours has increased from 67% to 81% in men and from 50% to
85% in women between the two cohorts. The prevalence and rise in
HPVþ ve tumours in the Scottish population is more in keeping
with the reported prevalence in the Stockholm population
where 93% of the tonsillar SCC in 2006–2007 were HPVþ ve
(Nasman et al, 2009) than that of the United States of America (72%
of oropharynx HPVþ ve between 2000 and 2005 (D’Souza et al,
2010)) or Australia (60% HPVþ ve 2005–2006 (Hong et al, 2010)).
The quality of data was good for age, stage, anatomical sub-site,
treatment and follow-up, but we were unable to find complete data
on smoking and drinking, which limited our analysis. Likewise
we were able to retrieve tissue blocks for most patients on which
p16 analysis could be performed. Human papillomavirus status
could not be determined for approximately 30% of the cases owing
to specimen quality. In these cases dilution of template DNA did
not improve amplification (data not shown). Degradation of
nucleic acid from paraffin-embedded blocks, particularly those
stored in excess of 5 years, is well documented (Gilbert et al, 2007).
p16 was the most significant prognostic variable, which concurs
with other studies.
The effect of smoking reported in other major studies (Ang et al,
2010) did not appear as a significant variable in the multivariate
analysis, but this may have been due to the very strong association
between p16 status and smoking. Interestingly, 75% of smokers
were p16 and 82% of non smokers were p16þ . When Kaplan–
Meier survival curves are created for the study population
as a whole, survival for past smokers lies mid-way between
non-smokers and current smokers.
The striking finding in this study was that the improvement in
survival between the first and second cohorts appeared because of
improved outcome in the HPVþ ve/p16ve patients with a 5-year
cause-specific survival of 36% in the earlier cohort compared with
73% in the later cohort (P¼ 0.0001). As reported by other
investigators, HPVþ ve/p16þ ve patients had excellent survival
and HPVve/p16ve tumours had the worst survival (Smith et al,
2008). The survival difference was not easily explained by smoking
and excessive alcohol intake, as if anything the second cohort
contained more current smokers and heavy drinkers. The major
difference in treatment between the two cohorts in Class-II was a
greater use of chemotherapy in addition to radiation (19 out of
31 (61.2%) in the later cohort compared with 5 out of 16 (31.2%) in
the earlier cohort).
We believe these results indicate that the HPVþ ve/p16ve
patients are a distinct group who particularly benefit from the use
of chemotherapy in addition to radiation.
Comparing the two cohorts did show that the later cohort
contained a higher proportion of HPVþ ve tumours and that
there were more non-smokers in the second cohort. The increase
in HPV positivity and number of non-smokers in the second
cohort was similar for men and women. Multivariate analysis
suggested that the difference in survival was therefore caused by a
change in treatment (predominantly to an increase in the use of
chemotherapy) and a difference in T stage. This is in agreement
with a major meta-analysis of randomised trials showing that, in
the primary setting, chemotherapy in addition to radiation
compared with radiation alone was beneficial (Pignon et al,
2000).
We were unable to address the addition of chemotherapy to
radiation in the post-operative setting as only one patient received
this treatment. Weinberger was the first to report a ‘three-class
hypothesis’ (Weinberger et al, 2006). He called (HPVþ ve/
p16þ ve) HPV-active Class-III 18 out of 78; (HPVþ ve/p16ve)
HPV-inactive Class-II 29 out of 78; and (HPVve/p16ve) HPV-
negative Class-I 30 out of 78. All the patients included in their
study had received either radiation alone or surgery with post-
operative radiation. In Weinberger’s study patients in Class-III had
5-year DFS of 75% vs 15% for patients with Class-I and 13% for
patients with Class-II. Interestingly the local recurrence rate was
higher in Class-II (74%) than in Class-I (45%) and Class-III (14%).
Our 5-year local recurrence rates were 13.5% for Class-III, 36.2%
for Class-II and 51.8% for Class-I. The increased percentage of our
patients falling into Class-III likely reflects not only a higher
prevalence of HPVþ ve tumours in our population, but also the
time period covered by the two studies, 1980–99 in Weinberger’s
study and 1999–2005 for ours. The poor outcome of the Class-II
patients in Weinberg’s study (the vast majority of whom received
no chemotherapy) mirrors the outcome of our Cohort-1 patients,
adding weight to the suggestion that the improved outcome seen in
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Figure 3 Kaplan–Meier plots illustrating (A) the overall survival, (B) the
frequency of loco-regional relapse and (C) the frequency of metastatic
relapse of patients in cohorts 1 and 2 according to HPV and p16 status.
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the Class-II patients in Cohort-2 of our study was caused by the
increased use of chemotherapy.
Controversy exists as to whether the HPV-inactive Class-II
(HPVþ ve/p16ve) exists as a discrete clinical entity. It is
interesting that in a recent study of 239 cases, Lewis et al (2010)
found only five to be HPVþ ve/p16ve using DNA ISH. A
conclusion of this study was that p16 testing alone would be
sufficient for delineation of meaningful clinical categories, but
importantly PCR was not performed on the p16ve cases. Our
data would not only strongly support the existence of this separate
molecular group, but would also indicate an important role for the
use of chemotherapy in this subgroup.
It is possible that our assignment of patients to HPV/p16 classes
could be affected by technical issues such as false positivity of the
HPV assay in the HPVþ ve/p16ve tumours. If this was the case
then the true assignment of this class would be HPVve/p16ve
and this is unlikely as the survival of our HPVþ ve/p16ve
patients in Cohort-2 was much closer to that of HPVþ ve/p16þ ve
patients than it was to that of HPVve/p16ve patients. The
different behaviour is in itself suggestive that the HPVþ ve/
p16ve class is a discrete clinical entity.
In terms of a mechanism behind our observations, the HPV-
encoded oncoproteins E6 and E7 are responsible for HPV-
associated tumorigenesis in oropharyngeal and other cancers. E6
causes degradation of p53 through ubiquitin-mediated proteolysis
(Wiest et al, 2002). As such, E6-expressing cells are not capable of
a normal p53 response and show features of genomic instability
(Duensing and Munger, 2004). E7 binds to and inactivates pRb,
causing the cell to enter S-phase, resulting in cell-cycle disruption,
proliferation and malignant transformation. Inactivation of pRb
also results in upregulation of p16 (Wiest et al, 2002). The
combined effect of E6 and E7 on the p53 and pRb pathways,
respectively, while resulting in tumorigenesis may both contribute
to the high radiosensitivity and chemosensitivity of HPVþ ve/
p16þ ve tumours reported here and elsewhere. It is possible that
either through abrogation of the effect of E7 or as a result of
epigenetic or mutational silencing of host p16 (O’Regan et al, 2008),
the HPVþ ve/p16ve tumours lack the molecular consequences of
E7 expression and that one of the consequences of this is lower
radiosensitivity compared with HPVþ ve/p16þ ve tumours. It could
be argued that chemotherapy with agents such as platinum, to which
tumours with genomic instability are recognised to be sensitive, is
necessary to optimise the outcome in these patients.
This study confirms the excellent prognosis of HPVþ ve/
p16þ ve patients and lends evidence to the suggestion of
de-escalation of treatment trials in this group.
It identifies the HPVþ ve/p16ve group as a clinically distinct
entity and strongly supports the use of chemotherapy in addition
to radiation in this group. As this was a retrospective study we
would strongly propose a clinical trial to address this specific issue
and that further trials using novel strategies should be considered
in the HPVve/p16ve group.
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Appendix Protocol A2
Protocol for retrieval of antigen and antibody staining according to
the CINtec Histology kit.
Staining for p16 was performed using the CINtec Histology Kit
from MTM Laboratories (Heidelberg, Germany).
The kit contains all the necessary reagents for immunohisto-
chemical detection of the p16INK4a antigen. The kit is designed to
be used on paraffin-embedded tissue specimens. The staining was
performed on a BOND-maX automated stainer in an accredited
pathology lab and according to the manufacturer’s protocol.
The following steps were performed:
1. De-paraffinisation in xylene and rehydration in alcohol
solutions (ethanol 95% and 70%).
2. Epitope retrieval in a water bath at 95–99 1C for 10min.
3. Cool-down in epitope retrieval solution at room temperature
(20–25 1C) for 20min.
4. Rinse with wash buffer.
5. Quenching of endogenous peroxidase with a peroxidase-
blocking reagent (3% hydrogen peroxide) for 5min.
6. Rinse with wash buffer.
7. Application of primary antibody – mouse anti-human p16
antibody – for 30min and negative controls in parallel (please
see below).
8. Rinse with wash buffer.
9. Application of visualisation reagent (a polymer reagent
conjugated with horseradish peroxidase and affinity-purified
goat anti-mouse Fab0 fragments) for 30min.
10.Rinse with wash buffer three times.
11.Application of DAB-buffered substrate for 10min.
12.Rinse with wash buffer.
13.Rinse with deionised water.
14.Counterstaining with haematoxylin and mounting of slides with
permanent mounting media.
The p16 antibody, which is ready diluted, is a mouse anti-
human monoclonal antibody (clone E6H4 from MTM Labora-
tories, Heidelberg, Germany). The negative control also ready to
use is a mouse anti-rat oxytocin-related neurophysin antibody (rat
oxytocin-related neurophysin is not present in human tissues).
Table A1 Patient demographics and clinical characteristics according to
HPV and p16 status
HPV+ve,
p16+ve
HPV+ve,
p16ve
HPVve,
p16ve
99–01 03–05 99–01 03–05 99–01 03–05
Total referrals 26 51 22 34 29 18
Sex
Male 21 38 16 18 18 13
Female 5 13 6 16 11 5
Mean age 54.5 55.6 63.3 60.1 59.3 66.1
Male 54.0 54.7 61.3 58.7 64.4 66.7
Female 56.2 58.4 68.5 61.6 51.6 64.4
Sub-site
Tonsil 17 33 12 10 12 3
Palate 2 0 1 8 2 4
Base of tongue 5 16 7 7 12 6
Oropharynx, NOS 2 2 2 9 3 5
T
T1 10 13 6 13 8 2
T2 5 16 3 5 7 5
T3 4 12 4 5 5 3
T4 7 10 9 11 9 8
Table A1 (Continued )
HPV+ve,
p16+ve
HPV+ve,
p16ve
HPVve,
p16ve
99–01 03–05 99–01 03–05 99–01 03–05
N
N0 5 8 6 14 8 7
N1 4 5 5 6 5 2
N2 14 33 9 12 13 8
N3 3 5 2 1 3 1
NX 0 0 0 1 0 0
Stage
I 2 4 2 8 6 1
II 0 1 1 2 1 3
III 5 6 4 6 5 4
IV 19 40 15 18 17 10
Grade
1 0 2 2 2 3 0
2 9 8 4 13 15 5
3 13 25 5 6 2 6
X 4 16 11 13 9 7
Smoking
Never 6 18 2 1 0 2
Ex 7 16 2 5 2 3
Current 13 15 16 26 24 13
NK 0 2 2 2 3 0
Drinking
Never 3 3 0 3 0 1
Previous excess 1 4 0 4 1 1
Social 12 34 10 7 12 3
Excess 10 8 9 18 12 12
NK 0 2 3 2 4 1
DepCat
1 1 4 1 1 0 1
2 2 10 1 5 3 2
3 11 11 5 8 7 3
4 7 18 9 7 8 6
5 4 7 3 7 9 4
6 1 0 2 4 1 1
7 0 1 1 2 1 1
Treatment
Surgery 12 3 3 3 4 2
Rad XRT 24 49 16 28 19 14
Rad chemo 10 44 5 19 6 11
Surgery alone 2 1 0 3 2 1
Surgery+PORT 10 1 2 0 2 0
Surg POCRT 0 1 1 0 0 1
XRT alone 4 4 9 9 11 3
Concom chemo/RT 10 34 4 15 6 8
Chemo and XRT 0 9 0 4 0 2
No radical treatment 0 1 6 3 8 3
Abbreviations: CTXRT¼ concomitant chemotherapy and radiation; CXCT¼ neoad-
juvant chemotherapy followed by radiation; DepCat¼ socioeconomic deprivation
category; Rad Chemo¼ concomitant chemotherapy and radiation; Rad XRT¼ single-
modality radiation with curative intent; SCXRT¼ surgery with postoperative
chemotherapy and radiation; SU¼ surgery; SUXRT¼ surgery with postoperative
radiation; XRT¼ radiation alone.
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Table A2 Patient demographics and clinical characteristics for
HPVþ ve/p16–ve patients
99–01 03–05 P-value
Total referrals 22 34
Sex
Male 16 18 0.139
Female 6 16
Mean age 63.3 60.1 0.319
Male 61.3 58.7 0.511
Female 68.5 61.6 0.118
Sub-site
Tonsil 12 10 0.049
Palate 1 8
Base of tongue 7 7
Oropharynx, NOS 2 9
T
T1 6 13 0.836
T2 3 5
T3 4 5
T4 9 11
N
N0 6 14 0.587
N1 5 6
N2 9 12
N3 2 1
NX 0 1
Stage
I 2 8 0.545
II 1 2
III 4 6
IV 15 18
Grade
1 2 2 0.383
2 4 13
3 5 6
X 11 13
Smoking
Never 2 1 0.522
Ex 2 5
Current 16 26
NK 2 2
Drinking
Never 0 3 0.052
Previous excess 0 4
Social 10 7
Excess 9 18
NK 3 2
DepCat
1 1 1 0.702
2 1 5
3 5 8
4 9 7
5 3 7
6 2 4
7 1 2
Treatment
Surgery 3 3 0.570
Rad XRT 16 28 0.391
Rad chemo 5 19 0.014
Surgery alone 0 3 0.027
Surgery+PORT 2 0
Surg POCRT 1 0
Table A2 (Continued )
99–01 03–05 P-value
XRT alone 9 9
Concom chemo/RT 4 15
Chemo and XRT 0 4
No radical treatment 6 3
Abbreviations: CTXRT¼ concomitant chemotherapy and radiation; CXCT¼ neoad-
juvant chemotherapy followed by radiation; DepCat¼ socioeconomic socioeco-
nomic deprivation category; Rad Chemo¼ concomitant chemotherapy and radiation;
RAD XRT¼ single-modality radiation with curative intent; SCXRT¼ surgery with
postoperative chemotherapy and radiation; SU¼ surgery; SUXRT¼ surgery with
postoperative radiation; XRT¼ radiation alone.
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